The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics ...

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...

Not Vinay Prasad. The new top regulator of vaccines and gene therapies at the Food and Drug Administration has never shied ...

In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

Vinay Prasad will be the next director of the FDA's Center for Biologics Evaluation and Research, after Peter Marks was ...

The U.S. Food and Drug Administration has named Vinay Prasad, an oncologist who has previously criticized FDA leadership and ...

Prasad's appointment marks the latest addition of a medical skeptic and critics of COVID-19 policies to federal health leadership.

The FDA has chosen Dr Vinay Prasad, a professor at UCSF, to lead its Center for Biologics Evaluation and Research.

Vinay Prasad oversees vaccines, gene therapies and the blood supply. His views raise alarms for pharmaceutical companies and ...

Vinay Prasad, MD, MPH, a frequent critic of the FDA and COVID-19 lockdowns and vaccination policies, will be the next ...

WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...